Factory price High Purity Peptide Powder Abaloparatide CAS 247062-33-5

What is Abaloparatide?

Abalapatide is a polypeptide composed of 34 amino acid residues, and the preparation method of abalapatide is disclosed in the patent. First, 3 peptide resin fragments are synthesized by solid phase synthesis method, and then peptide fragments 2 and 3 are connected with the Chemicalbook segment 1 of the peptide resin sheet. However, this method requires lyophilization before the condensation of peptide fragments 2 and 3, and the production of peptide resin fragments 2 and 3 requires the use of a large amount of expensive 2-CTC resin, resulting in increased production costs.

abaloparatide is a selective activator of the parathyroid hormone receptor (PTH1 receptor), and due to its good osteogenic activity, drugs made from abaloparatide are advanced for clinical development for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.

Abaloparatide Usage

-Treatment of postmenopausal women with osteoporosis at high risk for fracture
-Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
-Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture

Product Introduction
Humanin (HN) is a small mitochondrial-derived cytoprotective polypeptide encoded by mtDNA. HN exhibits protective effects in several cell types, including leukocytes, germ cells, neurons, tissues against cellular stress conditions and apoptosis through regulating various signaling mechanisms, such as JAK/STAT pathway and interaction of BCL-2 family of protein. HN is an essential cytoprotective peptide in the human body that regulates mitochondrial functions under stress conditions. The present review aims to evaluate HN peptide's antiapoptotic activities as a potential therapeutic target in the treatment of cancer, diabetes mellitus, male infertility, bone-related diseases, cardiac diseases, and brain diseases. Based on in vitro and in vivo studies, HN significantly suppressed the apoptosis during the treatment of bone osteoporosis, cardiovascular diseases, diabetes mellitus, and neurodegenerative diseases. According to accumulated data, it is concluded that HN exerts the proapoptotic activity of TNF-α in cancer, which makes HN as a novel therapeutic agent in the treatment of cancer and suggested that along with HN, the development of another mitochondrial-derived peptide could be a viable therapeutic option against different oxidative stress and apoptosis-related diseases.

Our Company Introduction 

Factory Photos 

Packing and Shipping